Videos

Acalabrutinib could offer a high level of confidence for patients looking at a long course of disease.

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how common chronic lymphocytic leukemia is for younger individuals

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how the results of a longer term study differ for individuals who were younger with chronic lymphocytic leukemia as opposed to those who are older.

Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses ongoing trials assessing efficacy and safety of asciminib in the treatment of chronic myeloid leukemia.

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses what the results of the initial iFCR study showed and what the highlights of the longer-term follow up were for individuals with chronic lymphocytic leukemia.

Shannon M. Rotolo, PharmD, BCPS, discusses what prompts pharmacists to make physician referrals to patients with atopic dermatitis and offers some beneficial advice.

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how iFCR therapy increases the chance of functional cure for younger individuals with chronic lymphocytic leukemia.

Closing out their discussion on marginal zone lymphoma, the panel considers which future treatment strategies are most promising.

Moving beyond BTK inhibition in marginal zone lymphoma, expert panelists review other therapies and drug classes with indications in this setting.

Experts consider optimal approaches to administering therapy for CDI and share insight on available treatment guidelines.

Shared insight on the prevalence of recurring Clostridioides difficile infection and management strategies.

Lindsey Roeker, MD at assistant attending L1, Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses how the study design could affect future studies.

Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses how the ASCEMBL study data may impact treatment strategies and approaches for patients with chronic myeloid leukemia.

Lindsey Roeker, MD at assistant attending L1, Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses the study design and the sample demographics.

Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses the highlights of the study and how the add-on approach affect the treatment of CLL.

The body of research around acalabrutinib is becoming quite advanced, allowing clinicians to feel confident when treating patients.

Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses how the addition of umbralisib and ublituximab affect those being treated with ibrutinib.

Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses how asciminib has impacted the treatment landscape for chronic myeloid leukemia.

New data are being presented at ASH 2021 regarding the durable efficacy of acalabrutinib in chronic lymphocytic leukemia.

Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses some of the challenges and risk of ibrutinib as treatment for CLL.

Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses new longer-term efficacy and safety data from the pivotal phase 3 ASCEMBL study.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed how microbiome-based therapeutics may impact the current treatment landscape for C. diff infection and recurrent C. diff infection.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed the current burden of C. diff infection and recurrent C. diff infection.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, addressed the risk factors for C. diff infection and recurrent C. diff infection.

An FDA decision regarding Merck's COVID-19 oral antiviral is imminent, but a recent CMS decision could limit patient access.

A panel recently re-convened recently to develop guidance for AmpC-bearing gram-negative pathogens.

In this video, Dr. Sherman recommends strategies for solving drug therapy related problems common to long-acting antiretroviral agents, such as missed doses, adverse drug reactions and drug–drug interactions.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, addressed the relationship between gut microbiome and C. diff infection.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discusses the current treatment strategies for C. diff infection and recurrent C. diff infection, as well as the efficacy and safety of these treatments.

In an interview with Pharmacy Times, Thomas Lodise, PharmD, PhD, discussed new guidance released by the Infectious Diseases Society of America (IDSA) on the treatment of antimicrobial resistant gram-negative infections.